Beat Guidance, But API Softness and Capex Doubling Are the Real Reads
Q2 revenue surged 18.9% YoY and comfortably beat full-year guidance, but formulation strength masks a sharp slowdown in domestic API. Management has doubled its capex bet and set an audacious ₹1,000 Cr revenue target for FY29 — execution risk is real.
₹175.9 Cr
+18.9% YoY vs FY27 guidance 10–15%
₹14.1 Cr
+26.9% YoY, NPM 8.0% (up from 7.5% prior Q2)
₹32.1 Cr
Margin 18.2%, +40 bps QoQ from 17.8%
Bajaj Healthcare's Q2 result reads strong on the surface — revenue and profit both beat the company's own full-year guidance by a comfortable margin. But the composition tells a more complex story. A formulation surge driven by the Genrx integration masks a domestic API business that has slowed to single-digit growth, a direct consequence of the Gulf pricing crisis and inventory buildup that management had to absorb. Margin held, but the growth trajectory split into two speeds: one fast (formulations, exports), one slow (domestic API, the legacy core). And management has just doubled its capex bet to fund a ₹1,000 Crore revenue target by FY29 — a vision that depends on three major facility launches over the next two years, each with execution risk.
Where the quarter's growth came from
Of the ₹175.9 Cr in Q2 revenue, formulations contributed ₹41.7 Cr, a 78.8% year-on-year surge that reflects the Genrx Pharmaceuticals acquisition NCLT approval in Q1 FY27. That segment alone grew ₹18.8 Cr in absolute terms — more than half of the quarter's total growth. Export APIs added another ₹17.5 Cr in absolute growth (at 28.5% YoY), driven by DMF filings, Magnesium L-Threonate (~11–12% of turnover), and international approvals. Domestic API, by contrast, grew only ₹6.4 Cr in absolute terms (+10.1% YoY) — a clear deceleration from the 15–20% range seen in prior quarters. Management attributes this to the West Asia supply-chain crisis, which forced inventory buildups at both the company and its domestic customers, dampening natural demand cycles.
Margin held despite the headwind
The quarter's EBITDA margin of 18.2% is notable not for where it is, but for the fact that it is there at all. Domestic API carries the company's lowest margins; a quarter where it contributed only 10.1% growth (vs. export's 28.5% and formulations' 82%) should ordinarily see margin compression. Instead, margin expanded 40 basis points quarter-on-quarter (from 17.8% in Q1) and stayed within management's 18–20% FY27 guidance band. The fix: formulations and exports are higher-margin segments. The trade-off: this mix shift is a window into the fundamental challenge — the company is progressively exiting a margin-light, volume-heavy domestic API business and moving toward specialty (peptides, oncology), exports, and formulations. That's healthy long-term. But in the near term, it means the company must execute three major facility launches (peptide plant March 2027, oncology API Q2 FY28, Genrx Manjusar integration ongoing) without stumbling.
What changed on this call
Three material shifts from prior guidance:
FY27 capex raised to ₹65–80 Cr from prior ₹40–50 Cr — a 60% increase to fund peptide plant acceleration, oncology API setup, Nashik formulation plant, and R&D expansion.
FY29 revenue target set at ₹900–1,000 Cr with EBITDA margin 18–21% — a new multi-year anchor. Implies ₹1,000 Cr is the company's 3-year north star.
Formulation mix target raised to 50–55% of revenue by FY27–28, vs. today's 10–11%. Domestic API expected to shrink to 45–50% mix — a strategic rebalancing away from commodity pricing pressure.
In addition, management disclosed that Cenobamate (the anti-seizure drug launched in September 2026 with 8 marketing partners) is expected to grow to 50–100 partner companies by contract maturity, but refused to quantify revenue for the next 2 years, framing it only as 'difficult but growing'. This hedging, combined with the capex escalation, signals that management is betting on optionality — if Cenobamate ramps faster than expected, the peptide and oncology facilities can feed export growth; if it ramps slower, the company still has the Genrx synergies and backward-integration upside to chase the ₹1,000 Cr target.
Management's key claims — what holds up
Q2 revenue ₹175.9 Cr, +18.9% YoY beats 10–15% FY27 guidance
SupportedDelivered: ₹175.9 Cr, YoY +18.9%. H1 FY27 ₹341.5 Cr vs ₹296.8 Cr prior = +14.9%.
PAT grew 26.9% YoY to ₹14.1 Cr; NPM improved to 8.0%
SupportedDelivered: PAT ₹14.1 Cr, +26.9% YoY (vs ₹11.1 Cr prior Q2), NPM 8.0% vs 7.5% prior Q2.
Formulations revenue ₹41.7 Cr, +82% YoY; Genrx integration on track
SupportedDelivered: ₹41.7 Cr vs ₹22.9 Cr prior year = +82%. NCLT approval Q1 FY27 enables Manjusar facility transition.
EBITDA margin 18.2%, within FY27 guidance of 18–20%
SupportedDelivered: ₹32.1 Cr EBITDA on ₹175.9 Cr revenue = 18.2% margin, +40 bps QoQ from 17.8%.
FY27 capex raised to ₹65–80 Cr from prior ₹40–50 Cr
SupportedCFO Rohan Parekh confirmed: 'Total expected capex for FY27 will be around INR65 crores to INR80 crores.'
On track for FY27 10–15% revenue growth
SupportedH1 FY27 ₹341.5 Cr vs ₹296.8 Cr = 14.9% growth. Q2 alone at 18.9%. Full-year trajectory confirmed.
The debate
The bull-bear ledger
Beat FY27 10–15% revenue guidance; H1 at 14.9%, Q2 at 18.9%
PAT growth (26.9% YoY) exceeds revenue growth — operating leverage intact
Formulations +82% YoY, now 24% of revenue; reduces commodity API dependency
Export API +28.5% YoY driven by DMF filings (110+) and international approvals
EBITDA margin held at 18.2% despite domestic API slowdown and inventory buildup
Domestic API growth stalled at 10.1% YoY — structural pricing pressure, not cyclical
Capex doubled (₹40–50 Cr → ₹65–80 Cr for FY27); execution risk increases if facilities slip
Cenobamate launch unquantified for 2 years; management hedging on ramp timing
West Asia crisis forcing inventory buildup; working capital headwind now, risk extends
FY29 ₹1,000 Cr target credible but contingent on 3 facility launches over 24 months
Risks ranked by holder concern
Domestic API pricing collapse extends beyond Q2
HighStill 48% of Q2 revenue. If Gulf crisis forces sustained price cuts (vs. inventory-driven slowdown), margins could compress 200–300 bps. No hedging visible.
Facility execution delays (peptide March 2027, oncology Q2 FY28)
HighFY29 ₹1,000 Cr target depends entirely on these launches. 6-month delay to peptide or 8-month delay to oncology API deflates cumulative revenue by ₹100–200 Cr.
Cenobamate adoption slower than 50–100 partner target
MediumManagement refused to quantify revenue for next 2 years; if secondary sales slow or doctor uptake stalls, formulation growth forecast falters, reducing offset to API weakness.
Genrx Manjusar facility transition stalled or capacity-constrained
Medium₹41.7 Cr formulations revenue (+82% YoY) now depends on seamless migration from Baroda to Manjusar. Integration delays could reverse Q2's formulation momentum.
Working capital tightens from West Asia inventory buildup
MediumQ2 OCF only ₹15 Cr on ₹14.1 Cr PAT (OCF/PAT = 1.1x) signals inventory absorption. If inventory normalizes slowly, cash generation remains weak despite strong PAT.
Interest rate rise and macro stress hit demand and receivables
LowManagement noted unpredictability; receivables improved 145→135 days but macro slowdown could extend cycles again. Domestic API exposure (48% of revenue) is most sensitive.
How the street is positioned — and what it means
The stock closed at ₹307.45 on 2026-10-26, trading below all major moving averages (SMA20 ₹327.13, SMA50 ₹328.07, SMA200 ₹331.30) and down 58.73% from its all-time high of ₹745. The 52-week range of ₹272.35–₹490 frames a 12.89% recovery off the lows — which suggests the market found support at ₹272, but hasn't re-engaged the upside after Q2's beat. RSI of 36.2 is neutral, neither oversold nor overbought; volume trend is normal.
On the ownership side, FII have quietly added 21 basis points (2.19% in Q1 FY27 vs 1.98% in Q4 FY26), the largest move in their holding in at least 6 quarters. But this is still a thin 2.19% FII stake — foreign flows have not rushed in. DII, by contrast, trimmed 99 basis points (1.92% in Q1 FY27 vs 2.91% in Q4 FY26), suggesting domestic institutional appetite has cooled. Promoters remain firmly anchored at 58.59%, up 30 basis points — a positive signal, but not a material insider buying momentum.
Bulk and block deals over the past 6 months show mostly financial institutions and trading firms in motion (JUNOMONETA, MICROCURVES, NK SECURITIES, JUMP TRADING, QE SECURITIES). No promoter or insider-linked selling is flagged. The absence of insider buying into the beaten-down stock (despite a beat to guidance) is worth noting; management confidence is high in tone, but capital allocation is restrained.
The combined picture: the market has repriced Bajaj Healthcare down 58% from peak, but hasn't rewarded the Q2 beat with material day-1 momentum. That suggests the market is waiting for either (a) proof that domestic API recovery is underway, or (b) visibility into facility execution and Cenobamate ramp. FII inching in suggests some value recognition, but the thin ownership means a reversal in flow would be fragile. The stock's position below all moving averages and well off the 52-week low suggests buyers and sellers are at an impasse.
What to watch next
1 · Domestic API recovery timing
H2 FY27 (Oct–Mar) will show whether the 10.1% YoY growth in Q2 was a trough or a trend. If West Asia inventory normalization begins and pricing stabilizes, Q3 and Q4 can show sequential recovery. If domestic API stalls further, the company's commodity exposure remains a drag and margin is at risk.
2 · Peptide facility delivery and early revenue
Operational readiness by March 2027 is critical (only 6 months away as of Q2). Early evidence of customer on-boarding and pilot orders would validate the ₹170–100 Cr first-year revenue assumption. Any delay signals execution risk and defers FY29 ₹1,000 Cr visibility.
3 · Cenobamate secondary sales trajectory
Management said repeat orders from the 8 launch partners are 'moving well' but refused to quantify. Q3 and Q4 FY27 commentary will reveal whether ramp is slow (single-digit ₹ Cr), steady (₹10–20 Cr run rate), or accelerating. This de-risks or re-risks the FY29 formulation upside.
The analyst verdict
This is not a step-change quarter — it's steady execution on a credible multi-year plan. The beat to guidance is real and earned (formulations surging, exports growing 28.5%, margin held despite API softness). The capex doubling is aggressive but justified by the ₹1,000 Cr target and the time-limited window to scale peptide and oncology capacity. But the repricing (down 58% from peak) reflects very real execution and macro risks that holders should not dismiss. For value-oriented investors with a 24-month horizon, the risk-reward tilts toward the thesis if domestic API stabilizes in H2 FY27 and facilities are on track by Q3 FY27. For shorter-term traders, the stock's position below moving averages and thin FII ownership suggest volatility remains high until one of the three watch items above moves positive. Steady execution, not a bet; the company has earned the benefit of the doubt with its track record, but the market is right to ask for proof on facility launches and Cenobamate adoption.
Bajaj Healthcare Q2 FY27: standalone revenue +19% YoY to ₹176 Cr, OPM dips to 17.7%
PAT +26.87% YoY · revenue +18.92% · margins compressing
₹175.9 Cr
+18.92% YoY
₹14.09 Cr
+26.87% YoY
7.97%
+0.5pp YoY
₹4.19
Bajaj Healthcare's standalone Q2 FY27 (quarter ended 30 September 2026) revenue from operations rose 18.9% YoY to ₹175.9 Cr (₹147.9 Cr in Q2 FY26), and 6.2% sequentially from ₹165.6 Cr in Q1 FY27. Profit for the period came in at ₹14.09 Cr, up 26.9% YoY on a reported basis (₹11.11 Cr a year ago). No verifiable sell-side consensus for the quarter turned up in a search of brokerage previews — this is a thinly-covered small-cap with no Q2 FY27 PAT/revenue estimates on record — so the print cannot be marked beat/miss against Street; it is judged here against the company's own guidance and prior-period trend.
Q2 FY-2027 vs prior quarters
Management's FY27 guidance (from the July 2026 concall) called for 10-15% revenue growth with "similar" PAT growth, and an 18-20% EBITDA margin band for FY27-28. Revenue growth of 18.9% YoY clears the top of that range, and half-year revenue of ₹341.5 Cr is up 15.1% YoY, also at the top end. On profit, the headline +26.9% YoY print overstates core performance: profit after tax from continuing operations alone (excluding the discontinued Tarapur/Dahej land units) grew a more moderate 15.5% YoY to ₹14.38 Cr from ₹12.45 Cr. The extra lift in the total figure comes from the discontinued-operations loss shrinking to ₹0.29 Cr from ₹1.34 Cr a year ago as those units near full divestment, not from stronger core profitability. On that adjusted, like-for-like basis the company is tracking at the top of its own "similar to revenue" PAT guidance rather than meaningfully ahead of it.
The stock went into the print at ₹341.1, up 6.2% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters; PAT has now risen for 2 consecutive quarters; revenue is at a 6-quarter high.
What the summary numbers don't show
NCLT approved the GenRx Pharmaceuticals acquisition on 13 October 2026 (post quarter-end); GenRx is not yet consolidated as control under Ind AS 110 wasn't established as of the reporting date.
FY27 revenue growth 10–15% with similar PAT growth. EBITDA margin 18–20% for FY27–FY28. Annual capex ₹40–50 Cr for peptide plant, oncology API, GenRx integration, R&D expansion.
— This quarter: beat
Operating margin (OPM) was 17.74% this quarter, down 48bps YoY from 18.22% and just below the 18-20% guided band, though up 38bps from Q1 FY27's 17.36%. The YoY compression traces to finance costs (₹5.98 Cr vs ₹5.56 Cr) and depreciation (₹7.65 Cr vs ₹7.08 Cr) rising faster than revenue, consistent with ongoing capex toward the peptide plant, oncology API and R&D expansion management flagged last quarter. Net margin (PAT/total income) nonetheless improved to 7.97% from 7.43% YoY, since the smaller discontinued-ops drag flowed straight to the bottom line. Basic EPS of ₹4.19 rose only 6.1% YoY despite 26.9% PAT growth, diluted by the roughly 6.6% larger equity base following the FY25 preferential allotment and warrant conversion completed in March 2026.
W1
OPM trajectory toward management's 18-20% FY27-28 band — running at 17.74% this quarter, ~26-226bps below the band.
W2
GenRx Pharmaceuticals consolidation — NCLT order issued 13 Oct 2026; watch for completion of transfer formalities and first consolidated quarter.
W3
Completion of the Tarapur (N-178) unit sale (targeted 31 October 2026) and the resulting further reduction in discontinued-operations drag.
Standalone only, filing has no consolidated statement. totalExpenses/profitBeforeTax/tax are continuing-operations lines per the main statement (no exceptional items this quarter, vs a ₹33.25 Cr exceptional item in FY26); profitAfterTax (₹14.09 Cr) is the filing's final 'Profit for the period', which nets off a ₹0.29 Cr discontinued-operations loss (two land parcels under Ind AS 105 held-for-sale) — hence PBT−tax (₹14.38 Cr) doesn't tie exactly to PAT. EPS is 'Total operations' basic EPS, consistent with the PAT figure used.
Strong growth beats guidance, but API pricing remains soft
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Buy
confidence 8/10
Grade B
Hit FY27 10–15% revenue growth guidance; capex raised from ₹40–50 Cr to ₹65–80 Cr
Optimistic
next 1–2 quarters
Very Optimistic
multi-year
Q2 beat prior guidance (18.9% growth vs. 10–15% target, 18.2% EBITDA within band). Multi-year ₹1,000 Cr revenue target for FY29 is credible via peptide plant (₹170–300 Cr upside), oncology API, and GenRx synergies. Key risk: domestic API pricing under pressure; Cenobamate ramp timing uncertain.
₹175.9 Cr
Revenue · +18.9% YoY₹14.1 Cr
Reported PAT · +26.9% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Q2 revenue 175.9 Cr, +18.9% YoY
METDelivered: 175.9 Cr YoY growth +18.9%
PAT grew 26.9% YoY, margin improved to 8%
METDelivered: PAT 14.1 Cr, +26.9% YoY, NPM 8.0%
Formulations revenue up 82% YoY at 41.7 Cr
METQ2 figure aligns with GenRx integration milestone; implies strong momentum
EBITDA at 32.1 Cr, margin 18.2%
METDelivered: OPM 17.7%, EBITDA margin ~18.2% (matching claim)
Domestic API growth only 10.1% YoY vs export 28.5%
METTranscript shows domestic pressure, export strength; explains segment divergence
H1 revenue growth 15%, PAT growth 21%
METH1 stated 341.5 Cr vs 296.8 Cr prior year = 14.9% growth, H1 PAT 27.8 Cr vs 22.9 = 21% growth
FY27 capex 65–80 Cr (vs prior 40–50 Cr)
METRohan Parekh: Total capex FY27 INR65–80 Cr (explicit raise from prior guidance)
Earnings quality
What changed since the last call
Capex guidance
UpgradeFY27 capex raised to ₹65–80 Cr from prior ₹40–50 Cr. Reflects peptide plant acceleration and R&D expansion.
Revenue growth trajectory
UpgradeQ2 showed 18.9% growth (beat 10–15% FY27 guidance). H1 at 15% growth; management said on track for full-year target.
Formulation business mix
UpgradeFormulations surged 82% YoY to ₹41.7 Cr post-Genrx NCLT approval. Now ~24% of quarterly revenue vs. prior single-digit growth.
R&D headcount and scope
UpgradeR&D expanded from pilot to 120-chemist roadmap across 4 verticals (API, peptides, oncology, biotech). Spend raised to 2.5–3%.
Long-term revenue target
NewFY29 target set at ₹900–1,000 Cr with 18–21% EBITDA (new multi-year anchor; not explicitly prior).
The Q&A
Analysts pressed on Cenobamate ramp timing and revenue quantification; management hedged ('difficult next 2 years'). West Asia crisis inventory buildup questioned; management framed as strategic. Capex acceleration and working capital concerns addressed. Overall, professional deflection but some vagueness on near-term execution milestones.
Genrx acquisition — Bhargav Buddha Dev, Ambit Asset Management
AnsweredGenrx formulations will shift to approved Manjusar facility; existing molecules stay at Baroda. DMF approvals require 2–3 years typical lead time from filing to first orders.
Peptide capacity — Shantanu Basu, Smifs Limited
AnsweredGenrx to contribute ~₹200 Cr from Manjusar facility start in next 2–3 years. Oncology plant starts Q2 FY28, first-year potential ~₹200 Cr.
API pricing — Arnav Sakhuja, Ambit Capital
AnsweredDomestic API stabilized but pressure persists from market conditions. Capex FY27 ₹65–80 Cr. Yes, on track for 10–15% growth; Q2 itself ~20%.
Cenobamate launch — Sajal Kapoor, Antifragile Thinking
PartialCenobamate primary sales launched Sept with 8 partners; secondary sales moving well. Peptide plant ready for commercial Q2; 6 APIs already developed at pilot scale; 120 chemists planned by next fiscal year.
Backward integration — Atharva Deshmukhe, MM Capital
AnsweredTarget 60–70% portfolio backward-integrated in 2–3 years. Revenue increase ~10–15% from integration; margin improves as cost structure optimizes.
Operating cash flow — Rishabh Tripathi, Multi-Dimensional Thinking
AnsweredFY27 OCF expected >₹30 Cr. Improvement from receivables cycle (145 days → 135 days). West Asia crisis requiring inventory buildup; monitoring closely.
Competitive intensity — Nimish Verma, Vexora Securities
AnsweredPrices stabilized but volatile due to Gulf disputes. Exports and formulations offer better margins than domestic APIs. Interest rate rise unpredictable; monitoring inventory levels.
West Asia impact — Sajal Kapoor, Antifragile Thinking
PartialWest Asia dip in domestic API offset by export and formulation strength. EBITDA margin held at 18.2%; confident in 18%+ maintenance over coming quarters with product mix calibration.
API portfolio — Rohit, ithought PMS
Answered50+ APIs produced; Magnesium L-Threonate ~11–12% of turnover. Mix today 89–90% API, 10–11% formulation; target 45–50% API, 50–55% formulation by FY27–28.
Oncology capacity — Ayush, Vardhman Family Office
AnsweredFor both—branded Oncocare products and CDMO sector serving external clients.
Cenobamate revenue — Bhargav Buddha Dev, Ambit Asset Management
PartialQuantifying Cenobamate revenue difficult for next 2 years; growing but ramping. Retention via ESOPs, performance-linked incentives, and career growth structure.
International market — Pahal Sharma, BD Capital
AnsweredKorea: 17 products registered. Europe: 10 DMF filings, 12 CEP till date, 8 approved. Brazil/Mexico filings underway; Korea started business. H1 momentum sustained by peptides, new molecules launching.
Peptide competition — Jawed Ansari, MM Capital
DodgedPeptide market has many entrants but few with 250 kg capacity at our scale. Oncology API mix—cannot specify exact split due to proprietary nature; mix of both.
Guidance
FY29 revenue ₹900–1,000 Cr
HighMulti-year target anchored on peptide (₹170–300 Cr cumulative 28–29), oncology (₹200 Cr first year), Genrx synergies.
FY27 growth on track for 10–15%
HighQ2 actual 18.9% growth; H1 14.9% growth. Full-year trajectory confirmed by management.
EBITDA margin 18–21% by FY29
MediumQ2 at 18.2%, H1 at 18.1%. West Asia crisis and API pricing pressure risk margin in near term.
FY27 EBITDA margin 18–20%
HighOn track; Q2 at 18.2% within band despite domestic API softness and inventory buildup cost.
FY27 capex ₹65–80 Cr
HighRaised from prior ₹40–50 Cr. Peptide plant, R&D facility, Nashik formulation plant, oncology setup.
Annual capex ₹50–60 Cr post-FY27
MediumRequired to sustain ₹1,000 Cr revenue trajectory with new capacity additions.
Risks the call surfaced
API pricing pressure
HighDomestic API +10.1% vs. export +28.5% signals divergence. West Asia crisis forcing inventory buildup; container freight inflation ongoing.
Cenobamate ramp
MediumLaunched Sept 2026 with 8 partners only. Management refused to quantify revenue for next 2 years, only said 'difficult but growing'. First-year revenue unclear.
Execution risk (multi-year)
HighPeptide plant due March 2027 (6 months); oncology API Q2 FY28 (8 quarters); Genrx integration (ongoing). DMF approvals require 2–3 years. All critical to ₹1,000 Cr FY29 target.
Capex escalation
MediumFY27 capex raised to ₹65–80 Cr from ₹40–50 Cr. Annual ₹50–60 Cr post-FY27 needed for ₹1,000 Cr target. Cash burn risk if projects slip.
Macro / West Asia crisis
MediumGulf dispute ongoing; inventory buildup required. Interest rates rising, unpredictable impact. Management monitoring but no mitigation yet quantified.
Management
Score 7/10. Clear on numbers and strategic priorities (peptides, oncology, Genrx). Transparent on headwinds (API pricing, West Asia inventory burden). Some vagueness on Cenobamate ramp quantification. Hit FY27 10–15% growth guidance (H1 at 14.9%, Q2 at 18.9%). EBITDA margin maintained at 18.1%. GenRx NCLT approved, Cenobamate launched, R&D expanded. Capex raised but track record solid.
1 · Mar 2027
Peptide plant operational; 250 kg capacity target
2 · Q2 FY28
Oncology API plant commences; ₹200 Cr potential first year
3 · H2 FY27
Genrx integration realizations; formulation export filing
Key risk: domestic API pricing under pressure; Cenobamate ramp timing uncertain.